Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
83.09
-5.41 (-6.11%)
At close: Apr 28, 2026, 4:00 PM EDT
84.00
+0.91 (1.10%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Guardant Health Revenue
In the year 2025, Guardant Health had annual revenue of $982.02M with 32.88% growth. Guardant Health had revenue of $281.27M in the quarter ending December 31, 2025, with 39.37% growth.
Revenue (ttm)
$982.02M
Revenue Growth
+32.88%
P/S Ratio
11.10
Revenue / Employee
$391,868
Employees
2,506
Market Cap
10.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 982.02M | 243.01M | 32.88% |
| Dec 31, 2024 | 739.02M | 175.07M | 31.04% |
| Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
| Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
| Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.31B |
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.28B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.34B |
| Mettler-Toledo International | 4.03B |
| Charles River Laboratories International | 4.02B |
| Revvity | 2.86B |
GH News
- 9 hours ago - Why Is Guardant Health Stock Falling On Tuesday? - Benzinga
- 12 days ago - Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire
- 4 weeks ago - Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan - Business Wire
- 5 weeks ago - Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data - PRNewsWire
- 5 weeks ago - Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - Business Wire
- 6 weeks ago - Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership - Business Wire
- 6 weeks ago - New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare - Business Wire
- 6 weeks ago - Guardant Health Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts